Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 1, 2005, Pages 25-29

  Ley, Ludwin M ^a,b   Becker, A ^a   Luhmann R ^b   Sander, P ^b   Lucker P W ^a  

^a Inst fur Klin Pharmakologie IKP   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

Healthy volunteers; Helicobacter pylori negative; Pantoprazole; Ranitidine; Tachyphylaxis

Indexed keywords

HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ENTERIC COATED TABLET; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; TACHYPHYLAXIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GASTRIC MUCOSA; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MALE; OMEPRAZOLE; RANITIDINE; SULFOXIDES; TACHYPHYLAXIS;

EID: 14944340777     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.1.875433     Document Type: Article

References (30)

1. Jones, D.B., Howden, C.W., Burget, D.W. et al. Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2-receptor antagonist. Gut 1988, 29: 890-3.
2. Merki, H.S., Wilder-Smith C.H. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994, 106: 60-4.
3. Wilder-Smith, C.H., Merki, H.S. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol Suppl 1992, 193: 14-9.
4. Goodman, L.S., Gilman, A. Pharmacologic Basis of Therapeutics. Macmillan: New York 1970.
5. Hyman, P.E., Garvey, T.Q., Abrams, C.E. Tolerance to intravenous ranitidine. J Pediatr 1987, 110: 794-6.
6. Wilder-Smith, C.H., Ernst, T., Gennoni, M. et al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990, 35: 976-83.
7. Mathot, R.A., Geus, W.P. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. Clin Pharmacol Ther 1999, 66: 140-51.
8. Lachman, L., Howden, C.W. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000, 95: 57-61.
9. Wilder-Smith, C., Halter, F., Ernst, T. et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1990, 4: 15-27.
10. Smith, J.T., Gavey, C., Nwokolo, C.U. et al. Tolerance during 8 days of high-dose H2-blockade: Placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 1990, 4: 47-63.
11. Sandvik, A.K., Brenna, E., Waldum, H.L. Review article: The pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997, 11: 1013-8.
12. Nwokolo, C.U., Smith, J.T., Gavey, C. et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990, 4(Suppl 1): 29-45.
13. Vigneri, S., Termini, R., Leandro, G. et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995, 333: 1106-10.
14. Bustamante, M., Stollman, N. The efficacy of proton-pump inhibitors in acute ulcer bleeding: A qualitative review. J Clin Gastroenterol 2000, 30: 7-13.
15. Brunner, G., Creutzfeldt, W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol Suppl 1989, 166: 101-5.
16. Walan, A., Bader, J.P., Classen, M. et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989, 320: 69-75.
17. Gisbert, J.P., Gonzalez, L., Calvet, X. et al. Proton-pump inhibitors versus H2-antagonists: A mela-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001, 15: 917-26.
18. Parsons, M.E. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996, 8: 15-20.
19. Simon, W.A., Budingen, C., Fahr, S. et al. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991, 42: 347-55.
20. Steinijans, V.W., Huber, R., Hartmann, M. et al. Lack of pantoprazole drug interactions in man: An updated review. Int J Clin Pharmacol Ther 1996, 34: 243-62.
21. Radhofer-Welte, S. Pharmacokinetics and metabolism of the proton-pump inhibitor pantoprazole in man. Drugs Today 1999, 35: 765-72.
22. Fitton, A., Wiseman, L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996, 51:460-82.
23. Cheer, S.M., Prakash, A., Faulds, D. et al. Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003, 63: 101-32.
24. Chiba, N., De Gara, C.J., Wilkinson, J.M. et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997, 112: 1798-810.
25. Huang, J.Q., Hunt, R.H. Meta-analysis of comparative trials for healing esophagitis (EE) with proton-pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs). Gastroenterology 1998, 114: A154.
26. Hotz, J., Plein, K., Schonekas, H. et al. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Scand J Gastroenterol 1995, 30: 111-15.
27. Hollander, M., Wolfe, DA. Nonparametric Statistical Methods. John Wiley: New York 1973.
28. German Medicines Act (Gesetz über den Verkehr mit Arzneimitteln (AMG)) as revised July 1999.
29. Note for Guidance on Good Clinical Practice. 1997, CPMP/ICH/135/95.
30. Rendic, S. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: From the laboratory to the clinic. Croat Med J 1999, 40: 357-67.